Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
retinitis pigmentosa treatment
market8 mentionslast seen Nov 10, 2026
Treatment of inherited retinal disease causing progressive vision loss.
Relationships 3
Relationship
MOGENRYapplies toretinitis pigmentosa treatment
99% confidence5 supporting mentions
Either name opens that entity’s relationships.
Sources 5
- newsPR NewswireNov 5, 2026Nanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory Affairs
Biologics License Application (BLA) for MOGENRY for the treatment of retinitis pigmentosa (RP) with severe vision loss
- newsPR NewswireOct 29, 2026Nanoscope Therapeutics to Participate in Advanced Therapies USA 2026 in Boston
FDA has accepted and filed the Company's BLA for MOGENRY for the treatment of RP with severe vision loss
- newsPR NewswireOct 14, 2026Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain
the company's Biologics License Application (BLA) for MOGENRY for the treatment of retinitis pigmentosa (RP)
- newsPR NewswireOct 6, 2026Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting
the treatment of RP with severe vision loss
- newsPR NewswireSep 29, 2026Nanoscope Therapeutics to Present at Meeting on the Mesa 2026
MOGENRY has the potential to become the standard of care for patients with RP